Prothena Corp Public (PRTA) Cash from Financing Activities (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Cash from Financing Activities of -$6.9 million for Q1 2026, down 14370.83% year-over-year from N/an in Q1 2025, and down 40758.82% quarter-over-quarter from -$17000.0 in Q3 2025.
Analysis
Prothena Corp Public (PRTA) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Prothena Corp Public's Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$6.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 14370.83% year-over-year to -$6.9 million; the TTM figure through Mar 2026 stood at -$7.0 million (down 1150.3% YoY), while the FY2025 annual figure was -$139000.0, down 108.94% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$6.9 million, down from -$17000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $220.8 million in Q4 2022, with the low at -$6.9 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is $659500.0 (2023), against an average of $17.6 million.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities surged 12351.49% in 2022, then sank 14370.83% in 2026.
- Prothena Corp Public's Cash from Financing Activities stood at $220.8 million in 2022, then tumbled by 99.78% to $483000.0 in 2023, then plunged by 112.22% to -$59000.0 in 2024, then jumped by 71.19% to -$17000.0 in 2025, then sank by 40758.82% to -$6.9 million in 2026.
- Business Quant data shows PRTA's Cash from Financing Activities at -$6.9 million in Q1 2026, -$17000.0 in Q3 2025, and -$74000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Prothena Corp Public | 509.98 Mn | 221.78 Mn | - | -15.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.57 Mn |
| Mar 31, 2026 | -6.95 Mn |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -74,000.00 |
| Mar 31, 2025 | -48,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Sep 30, 2024 | 333,000.00 |
| Jun 30, 2024 | 444,000.00 |
| Mar 31, 2024 | 836,000.00 |
| Dec 31, 2023 | 483,000.00 |
| Sep 30, 2023 | 2.71 Mn |
| Jun 30, 2023 | 18.63 Mn |
| Mar 31, 2023 | 23.28 Mn |
| Dec 31, 2022 | 220.77 Mn |
| Sep 30, 2022 | 18.13 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 1.34 Mn |
| Dec 31, 2021 | 1.77 Mn |
| Sep 30, 2021 | 87.01 Mn |
| Jun 30, 2021 | 20.22 Mn |